Page not found
HOME / Page not found

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (522)

Friday, 14 October 2022 10:03

Andres Cardona

Written by
Friday, 14 October 2022 10:03

Khaled Tolba

Written by
Friday, 14 October 2022 10:03

Tabetha Sundin

Written by
Friday, 14 October 2022 10:03

Lesli Kiedrowski

Written by
Lesli Kiedrowski is the Director of Medical Affairs in Oncology at Guardant Health. She and her team collaborate with clinician and biopharma partners to advance the fields of liquid biopsy and precision oncology through research projects ranging from clinical utility and implementation of genomic profiling to exploratory biomarker assessment. Prior to joining the team at Guardant Health six years ago, Lesli worked in clinical care as a genetic counselor, primarily seeing patients for hereditary cancer risk assessment and management.
Friday, 14 October 2022 10:03

Hillary Stires

Written by
Hillary Stires serves as a Science Policy Analyst at Friends of Cancer Research (Friends). Friends is an advocacy organization based in Washington, DC that drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed life-saving treatments to patients. For more than two decades, Friends has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible. At Friends, Hillary supports the development and implementation of the organization’s research and policy agenda. She uses her scientific and advocacy background to develop evidence based policies. Hillary collaborates with diverse teams to identify challenges in cancer research and create solutions that improve and accelerate cancer care for patients. She runs Friends’ ctDNA for Monitoring Treatment Response (ctMoniTR) Project, a first of its kind partnership working to answer the important question: Do changes in ctDNA reflect response to treatment? Hillary received her PhD in endocrinology and animal biosciences from Rutgers University and completed a postdoctoral fellowship in tumor biology at Georgetown University’s Lombardi Comprehensive Cancer Center. Her research focused on tumor development and drug resistance in hormone dependent breast cancer.
Tuesday, 23 August 2022 20:14

Paz Vellanki

Written by
Paz Vellanki received her MD/PhD at the University of Maryland, School of Medicine. Her doctoral work was in Biochemistry and Molecular Biology and involved studying the molecular underpinnings of a hereditary colorectal cancer syndrome. She completed her residency in Internal Medicine at the Wake Forest, School of Medicine in Winston-Salem, North Carolina and her fellowship in Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. She is currently a team leader on the thoracic and head and neck cancer team at the U.S. Food and Drug Administration (FDA). At the FDA, she is also involved with efforts related to ctDNA and drug development. She continues to care for patients with head and neck cancer as a Clinical Assistant Professor at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
Tuesday, 23 August 2022 20:14

Jillian Phallen

Written by
Jillian Phallen, Ph.D. is an Assistant Professor of Oncology in the Division of Cancer Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. She is an investigator in the Cancer Genomics Laboratory with a research focus on liquid biopsy approaches and applications for noninvasive early detection of cancer. Dr. Phallen developed the targeted error correction sequencing (TEC-Seq) method for direct detection of circulating tumor DNA as well as an orthogonal approach for noninvasive detection of cancer called DELFI (DNA evaluation of fragments for early interception). She applied these approaches in the setting of early detection of cancer to assess the value of liquid biopsy tests for cancer screening. She also applied liquid biopsy approaches for disease monitoring to identify recurrence, track response to treatment, and detect minimal residual disease. The results of these studies have brought new advances to the field of cancer genomics and highlight the potential of liquid biopsy approaches to change patient care for the better in the future. Current research focuses on further understanding the mechanisms of cell-free DNA fragmentation and improving fragmentomics-based approaches for early detection of cancer.
Tuesday, 23 August 2022 20:14

Alberto Bardelli

Written by
After his undergraduate studies, Bardelli moved to the Ludwig Institute for Cancer Research in London where he obtained a Ph.D. in Biochemistry and Molecular biology from the University College London (UCL). He moved to the United States in 1999 for a post-doctoral fellowship in the laboratory directed by Bert Vogelstein at the Howard Hughes Medical Institute, Johns Hopkins University (Baltimore). Here Bardelli began studying the genomics of cancer. One of his most significant publications from that period identified for the first-time mutations in kinase genes (the kinome) that are associated with colorectal cancer. As an independent investigator, he pioneered the combined use of genomics, patients’ avatars to accurately predict tumor's response and resistance to targeted agents. Alberto Bardelli identified novel biological mechanisms of resistance and sensitivity to cancer therapies, defined how deficiencies in DNA repair pathways lead to tumor immune surveillance and pioneered the use of liquid biopsies to track cancer evolution. The results of his work led to changes in clinical practice for colorectal cancer patients. In 2022 Bardelli was appointed as Scientific Director of IFOM– The AIRC Institute of Molecular Oncology, Milan. Overall, he has authored more than 250 scientific articles of which over 100 as an independent investigator.
Tuesday, 23 August 2022 20:14

Nicola Fusco

Written by
Prof. Nicola Fusco is the Director of the Biobank for Translational and Digital Medicine Unit, senior pathologist of the Breast Unit at the Division of Pathology, European Institute of Oncology (IEO), Milan, Italy, and Associate Professor of Pathology at the Department of Oncology and Hemato-Oncology, University of Milan. He is a PI leading a multidisciplinary and international group of scientists focused on predictive pathology, molecular pathology, immunopathology, and digital pathology, particularly in breast cancer. He is the recipient of national and international awards and co-founder and Scientific Board member at 4oncommunity.com
Tuesday, 23 August 2022 20:14

Adam Widman

Written by
Page 29 of 38